Skip Navigation

University of Michigan Medical Center

Blood and Marrow Transplant Program
1500 East Medical Center Drive, SPC 5271
F4826 UH South
Ann Arbor, MI 48109-5271
(734) 647-7745
(800) 865-1125
http://www.cancer.med.umich.edu/cancertreat/treatment/bmt/index.shtml

Number of Transplants Performed

This center has been performing allogeneic transplants since 1990 and has been an NMDP transplant center since September 1994.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
7 83 9 --- 99
Unrelated Donor
- Pediatric
20 2 8 --- 30
Related Donor
- Adult
9 72 0 --- 81
Related Donor
- Pediatric
9 1 0 --- 10
Autologous
- Adult
--- --- --- 258 258
Autologous
- Pediatric
--- --- --- 27 27
Total
(by cell source)
45 158 17 285 505

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

The University of Michigan


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2010, 2011 and 2012, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 332 patients.

The actual 1-year survival of these patients is 64.1%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 58.6% and 68.3%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

University of Michigan Medical Center - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 -- -- 4/5 3/3 7/7 2/4 17/20
Acute lymphoblastic leukemia in second complete remission -- 1/1 2/2 -- -- 1/1 -- 4/4
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 1/1 -- -- 1/1
Acute myelogenous leukemia in first complete remission -- 1/1 1/3 1/1 3/5 5/10 5/6 16/26
Acute myelogenous leukemia in second complete remission -- -- -- -- 3/3 3/4 0/1 6/8
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/1 1/2 1/2 3/12 4/4 10/21
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 2/2 1/5 3/7
Chronic myelogenous leukemia in first chronic phase -- -- 1/1 -- 1/1 -- 1/1 3/3
Disorders of the immune system -- -- 1/1 -- -- -- -- 1/1
Inherited abnormalities of erythrocyte differentiation or function 3/3 2/2 -- -- -- -- -- 5/5
Multiple myeloma / Plasma cell disorder -- -- -- -- 2/5 3/6 0/3 5/14
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- -- 2/3 1/3 3/6
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- 1/1 -- 1/1 2/4 0/2 4/8
Myelodysplastic disorders - Other MDS -- -- -- -- -- 1/1 2/2 3/3
Myeloproliferative syndromes -- -- -- -- -- 2/4 1/2 3/6
Non-Hodgkin lymphoma -- -- -- 0/1 4/4 5/7 3/5 12/17
Other acute leukemia -- 1/1 -- -- -- -- -- 1/1
Severe aplastic anemia -- 2/2 1/1 -- 1/1 -- -- 4/4
Total 4/4 7/7 8/10 6/9 20/26 36/61 20/38 101/155

University of Michigan Medical Center - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/2 2/3 -- 0/1 3/4 0/2 0/1 6/13
Acute lymphoblastic leukemia in second complete remission -- -- -- -- -- -- 1/1 1/1
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure 3/3 2/4 -- -- -- 0/1 0/2 5/10
Acute myelogenous leukemia in first complete remission -- 2/2 1/1 3/4 2/4 12/14 7/11 27/36
Acute myelogenous leukemia in second complete remission -- 1/1 0/2 -- 2/2 0/2 1/2 4/9
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/2 -- 0/1 1/4 3/6 4/13
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/1 0/2 -- 1/3
Chronic myelogenous leukemia in first chronic phase 1/1 -- 1/1 -- -- -- -- 2/2
Disorders of the immune system 1/2 -- -- -- -- -- -- 1/2
Histiocytic disorders 1/1 -- -- -- -- -- -- 1/1
Inherited abnormalities of erythrocyte differentiation or function -- 1/1 -- -- -- -- -- 1/1
Multiple myeloma / Plasma cell disorder -- -- -- -- 2/2 4/7 1/3 7/12
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- 1/1 1/2 -- -- 1/1 1/1 4/5
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- 1/1 -- -- -- 1/2 2/5 4/8
Myelodysplastic disorders - Other MDS -- -- -- 1/1 -- 1/2 3/3 5/6
Myeloproliferative syndromes 0/1 -- -- -- 2/4 -- 1/2 3/7
Non-Hodgkin lymphoma -- -- 1/1 0/1 4/6 8/12 4/8 17/28
Other acute leukemia 1/1 1/2 -- -- -- -- -- 2/3
Severe aplastic anemia 4/4 0/2 -- -- 0/1 -- -- 4/7
Total 12/15 11/17 4/9 4/7 16/25 28/49 24/45 99/167

Program Description:

The vision of the U-M Blood and Marrow Transplant Program is to create a future where transplantation is safer, more effective and eventually, less common. Our adult and pediatric programs are internationally recognized for expertise in transplantation. More than 200 BMT procedures are performed at U-M each year-making us one of the largest programs in the state of Michigan. Our program is patient-focused and research-driven. We offer a robust program of basic, clinical and translational research. We also have one of the top Extra Corporeal Photopheresis (ECP) programs in the world providing cutting-edge therapies to transplant patients with graft-vs-host disease (GVHD), Our program is accredited by the Foundation for the Accreditation of Hematopoietic Cell Therapy and is certified by the National Marrow Donor Program.

Contact Information:

If you have transplant-related questions, please contact Lisa Hoekstra, transplant center coordinator, at (734) 232-7587 or by e-mail at lhoekstr@umich.edu.

Program Type:

Both

Attending Physicians:

(Medical Doctors)

Adult -

Daniel Couriel, Steve Goldstein, John Magenau, Brian Parkin, Reddy Pavan, Attaphol Pawarode, Mary Riwes, Gregory Yanik

Pediatric -

Craig Byersdorfer, Sung Choi, Jim Connelly, Andy Harris, Carrie Kitko, John E. Levine, Gregory Yanik

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Joan Taylor by e-mail at jotay@umich.edu or by phone at (734) 936-7804.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.